Medicare drug price negotiations: The first drug list is here!
The list of ten drugs for Medicare price negotiation has been published! What do we know about these Medicare "blockbusters"? And how are drugmakers taking the news? More
Defining “better”: A look at the new Alzheimer’s drugs
Unlike its predecessor drug aducanumab, lecanemab actually showed a statistically significant difference in slowing cognitive decline in its clinical trial. But can the drug improve patients’ quality of life? More
When it comes to prescription drugs, are we getting what we pay for?
Two recent analyses of expensive medications indicate that many drugs are being priced above their actual clinical benefit. More
The slippery slope of the mifepristone and the FDA
An ongoing lawsuit focusing on the FDA's approval of the abortion pill mifepristone could open the door to drug regulatory chaos. More
After decades of profiteering, insulin manufacturer finally cuts the price
Insulin manufacturer Eli Lilly announced that it would be cutting the list price of its generic insulin products significantly. This move comes after decades of advocacy work by patients and clinicians alike, including our sister organization the Right Care Alliance. What does this tell us about the drug pricing landscape? More
A tale of two drugs: Accountability and evidence in Alzheimer’s treatments
An investigation of one Alzheimer's Disease drug and the approval of another offer lessons on accountability and evidence for new drug approvals. More
Power to the People: How a single tweet could reignite a movement
With $8 and 9 words, one internet troll is forcing insulin manufacturers to answer the question of why the drug is so unaffordable More
1.3 million Americans forced to ration insulin, new study estimates
Skipping doses, intentionally undermedicating, not eating - these are all measures 1.3 million Americans are forced to take to keep their insulin costs down. More
Balancing hope and uncertainty: The controversy behind the new ALS drug
The reasoning behind this decision has to do with a complex bioethical question - if there is the potential to treat a previously untreatable disease with a new pharmaceutical, but the consequences are unknown, do you prescribe the drug? Is the unknown enough to deny patients hope? More
A win for Medicare patients and their wallets
The Inflation Reduction Act allows Medicare to negotiate drug prices and cap insulin costs...but only for Medicare enrollees. More
Hospitals were making progress on antibiotic stewardship…then COVID-19 arrived
Deaths from antibiotic-resistant infections were decreasing, until COVID-19 happened. How does this reflect our pill-for-every-ill culture? More
The Cerebral scandal brings ADHD overprescription into the spotlight
A telehealth company's downfall sheds light on the overprescription of stimulants to ADHD patients More
How mental health apps can accelerate the psychiatric prescribing cascade
Mental health apps designed to improve access to care may be driving overdiagnosis and overmedication, a recent investigation finds. More
When meds taken “as prescribed” still cause harm
A group of advocates has been sounding the alarm about the risk of side effects from benzodiazepines, even when taken as directed. An upcoming documentary tells their stories. More
How electronic tools can help deprescribe in the hospital
The Medsafer study shows how clinical decision tools can help doctors deprescribe more in the hospital. More
How we achieve equal access to pharmaceutical treatment
Research shows that people of color are more likely to experience underuse of needed medications. How do we achieve equity in access to affordable, high-quality medications? More
Why are dentists still overprescribing opioids?
Despite the known risks, dentists still prescribe too many opioids to young adults and teens. How can we reverse this pattern? More
Stop taking aspirin for primary prevention, task force says
Does an aspirin a day keep the doctor away? It used to be the conventional wisdom that taking low-dose aspirin helped prevent a first heart attack or stroke. However, the evidence isn't there to back up this practice. More
Most Medicare patients with dementia wouldn’t have been eligible for Aduhelm trials
The FDA approved Alzheimer's drug Aduhelm for all people with mild dementia -- but most of this population is at an increased risk of side effects from the drug. More
New Alzheimer’s drug may burden state budgets
State budgets are already being squeezed by rising health care costs, leaving less for public health and social spending. How will the cost of new Alzheimer's drug Aduhelm impact Medicaid costs and state budgets? More